Summary:
Chinook Therapeutics, Inc. / “A Phase 1, Single Center, Randomized, Placebo-Controlled, Double Blind Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CHK-336 in Healthy Volunteers”
Qualified Participants Must:
• 18-45 years old
• No Rx meds
• Hormonal birth control is ok
• Non-smoker
• must pass a drug screen
• requires a 19-night stay at our Phase 1 unit in Cincinnati, OH plus 2 outpatient visits
Qualified Participants May Receive:
Compensation up to $8,950